Phase I/II trial of RAD001 plus Nexavar for patients with metastatic renal cell carcinoma.

Trial Profile

Phase I/II trial of RAD001 plus Nexavar for patients with metastatic renal cell carcinoma.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 22 Mar 2016

At a glance

  • Drugs Everolimus (Primary) ; Sorafenib
  • Indications Renal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 10 Nov 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 23 Sep 2008 Planned end date changed from 1 Apr 2009 to 1 Aug 2009.
    • 24 Aug 2008 The expected completion date for this trial is now 1 Apr 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top